Beta Pharmaceuticals

Betta Pharmaceuticals is a leading Chinese biopharmaceutical company specializing in the discovery, development, and commercialization of innovative oncology therapies. The company gained international recognition with the launch of Conmana (icotinib), the first indigenously developed small molecule targeted anti-cancer drug in China, which has become a standard of care for EGFR-mutant non-small cell lung cancer. Betta maintains a diverse pipeline of small molecules and biologics, focusing on high-incidence cancers such as lung, breast, and renal cell carcinoma. With multiple R&D centers in China and the United States, the company leverages strategic partnerships to advance its global clinical programs. Betta is publicly traded on the Shenzhen Stock Exchange and is considered a cornerstone of the Chinese innovative pharmaceutical industry.